Publication | Open Access

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction

ThrombosisCell TherapyBone Marrow FailureCardiovascular DiseasePlacebo-controlled Pilot TrialHematologyMedicinePhase IiCardiologyEmergency MedicineAcute Myocardial InfarctionMyocardial Infarction